191124_PhagoMed_Logo_ohneSubline dn.png
  • About us

    • Company
    • Team
  • Technology

    • LysinBuilder platform
    • Pipeline
    • Background
  • PM-477

  • News

  • Career

  • Contact

  • More

    Use tab to navigate through the menu items.
    • zwitschern
    • LinkedIn Social Icon
    • All Posts
    • 2020
    • 2019
    • 2018
    PhagoMed named a Finalist in Extreme Tech Challenge 2021
    alexanderbelcredi
    • Jun 17, 2021

    PhagoMed named a Finalist in Extreme Tech Challenge 2021

    PhagoMed has been named a Healthcare Category Finalist in the Extreme Tech Challenge 2021. The company was selected out of more than...
    PhagoMed graduates from NYU Stern School of Business EFL program
    alexanderbelcredi
    • May 5, 2021

    PhagoMed graduates from NYU Stern School of Business EFL program

    Among more than 500 applicants, PhagoMed was selected in autumn 2020 to participate in the Endless Frontiers Lab (EFL) acceleration...
    Published: ɛ2-phages are naturally bred and vastly superior to wild-type
    alexanderbelcredi
    • Apr 7, 2021

    Published: ɛ2-phages are naturally bred and vastly superior to wild-type

    PhagoMed published details on its phage program PM-399 including a detailed introduction to its proprietary ɛ2-(evolution...
    First patient successfully treated with ε2 phage
    alexanderbelcredi
    • Mar 29, 2021

    First patient successfully treated with ε2 phage

    PhagoMed partnered with Yale University and the University of Maryland School of Medicine to provide intra-articular phage therapy to a...
    PhagoMed selected for Phase III of EIT Health's Gold Track program
    alexanderbelcredi
    • Feb 25, 2021

    PhagoMed selected for Phase III of EIT Health's Gold Track program

    Since June 2020, PhagoMed has been part of the Gold Track program, the premier European life sciences accelerator. Following the...
    Published: Breakthrough therapy for recurrent bacterial vaginosis
    alexanderbelcredi
    • Jan 13, 2021

    Published: Breakthrough therapy for recurrent bacterial vaginosis

    An engineered phage endolysin could offer a highly innovative and precise therapy for recurrent bacterial vaginosis, a disease for which...
    PhagoMed Selected as Leading Young European Biotech Company
    alexanderbelcredi
    • Dec 4, 2020

    PhagoMed Selected as Leading Young European Biotech Company

    PhagoMed Biopharma GmbH came 2nd and won €20.000 in one of the toughest contests for young European biotech companies, namely the Health...
    PhagoMed wins Medical Biotech track at Hello Tomorrow competition
    alexanderbelcredi
    • Nov 17, 2020

    PhagoMed wins Medical Biotech track at Hello Tomorrow competition

    Earlier this year, PhagoMed was selected to compete at the Hello Tomorrow Global Challenge 2020 in 'Medical Biotech' track. The...
    Pre-Print: Novel solution for recurrent bacterial vaginosis published on MedRxiv
    alexanderbelcredi
    • Oct 28, 2020

    Pre-Print: Novel solution for recurrent bacterial vaginosis published on MedRxiv

    Press Release, Vienna (Austria), 28th October 2020: An engineered phage endolysin could offer a highly innovative and precise therapy for...
    1
    234

    BioNTech R&D (Austria) GmbH

    Leberstraße 20

    1110 Vienna

    Austria

    contact@phagomed.com

    ​

    Imprint & Privacy Policy